How to Buy Eli Lilly & Co Stock
Eli Lilly & Co
Eli Lilly & Co is a general drug manufacturer company located in Indiana, United States, which is part of the Healthcare sector, and is traded under the ticker LLY on the NYSE exchange.
Eli Lilly & Co stock last closed at $745.95, down 0.64% from the previous day, and has increased 101.66% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.91 percentage points. Eli Lilly & Co stock is currently +101.74% from its 52-week low of $369.76, and -6.85% from its 52-week high of $800.78.
At the moment, there are 950.16M shares of LLY outstanding. The market cap of LLY is $708.78B. In the past 24 hours, 1.7M LLY shares were traded.
How to Buy Eli Lilly & Co Stock
Wondering how to invest in Eli Lilly & Co stock? Here's how.
- Figure out where to buy Eli Lilly & Co stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you choose where to buy Eli Lilly & Co stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Choose your payment method and add your info.
- Evaluate Eli Lilly & Co stock: The Eli Lilly & Co ticker symbol is LLY. Is Eli Lilly & Co stock a good investment? Should you buy shares of LLY? How do LLY's underlying business fundamentals look? Do top analysts think Eli Lilly & Co is a good buy? Why has LLY's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if LLY is a good stock to buy).
- Make your LLY buy order: Decide if you will purchase LLY shares at the current market price or use a limit order to buy LLY stock at a given price.
- Keep tabs on your LLY investment: Create a watchlist to get live updates on your investment in Eli Lilly & Co stock.
Step 1: Figure out where to buy Eli Lilly & Co stock
You will need a brokerage account in order to access the NYSE market and buy LLY stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Energy, New York to Shanghai — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro now.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you can invest in LLY today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create your new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on the best app for stock investing, you need to deposit funds:
Check out the video below for more details transferring money into your new investment account.
Step 4: Evaluate Eli Lilly & Co stock
After you have identified the best place to buy Eli Lilly & Co stock, it's important to research their stock before you invest, so you can wrap your head around the risk and opportunity.
Eli Lilly & Co Metrics
Fundamentals of LLY
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis.
You can see all of the due diligence checks on LLY's stock page.
Is LLY stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge LLY's true value.
Using relative valuations ratios:
- LLY could be undervalued based on its P/E ratio of 128.17x, relative to Drug Manufacturers - General industry P/E ratio of 153.61x
- LLY may be overvalued based on its P/B ratio of 65.8x, relative to Drug Manufacturers - General industry P/B ratio of 5.77x
- LLY could be overvalued based on its PEG ratio of 2.38x
You can do additional valuation analysis on LLY's stock here.
LLY Financial Health Overview
Positive Financial Indicators:
- LLY earnings of $6.55B is not sufficient to cover its interest payments.
Negative Financial Indicators:
- Total LLY debt is higher than 5 years ago, relative to shareholder equity.
- There are more long-term liabilities than short-term assets on the LLY balance sheet.
- LLY has a relatively high debt to equity ratio of 4.93.
- There are more short-term liabilities than short-term assets on the LLY balance sheet.
- LLY's operating cash flow of $4.24B allows it to safely service it's debt of $25.23B.
- LLY profit margin has gone down from 21.9% to 15.4% in the past year.
Do Wall Street analysts think it's a good time to buy LLY stock
Out of 15 Equities analysts who give recommendations on LLY, the consensus analyst rating on LLY is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent LLY Analyst Upgrades/Downgrades
Geoff Meacham, a bottom 7% analyst from Bank of America maintains LLY with a strong buy rating and raises their LLY price target from $800.00 to $1,000.00, on Mar 1, 2024.
Bank of America's Geoff Meacham raised their price target on Eli Lilly & Co (NYSE: LLY) by 25% from $800 to $1,000 on 2024/03/01. The analyst maintained their Strong Buy rating on the stock.
Even with the stock's strong YTD performance, Meacham argued that Eli Lilly & Co "remains a favorite name among BoA's Biopharma portfolio based on peer-leading revenue growth, margin expansion, and a compelling pipeline."
Acknowledging that investors clearly see the commercial strength of Mounjaro in diabetes and Zepbound in obesity, the analyst pointed out that the company has additional opportunities in heart disease, obstructive sleep apnea, and liver disease that are "vastly underappreciated."
Elmar Kraus, a top 35% analyst from DZ Bank downgrades LLY to a hold rating and announces their LLY price target of $820.00, on Feb 21, 2024.
Terence Flynn, a top 7% analyst from Morgan Stanley maintains LLY with a strong buy rating and raises their LLY price target from $805.00 to $950.00, on Feb 16, 2024.
David Phung, a top 21% analyst from Morgan Stanley maintains LLY with a strong buy rating and raises their LLY price target from $763.00 to $805.00, on Feb 7, 2024.
Mohit Bansal, a top 8% analyst from Wells Fargo maintains LLY with a strong buy rating and raises their LLY price target from $700.00 to $825.00, on Feb 7, 2024.
You can dive deeper into what analysts are forecasting on the Eli Lilly & Co stock forecast page.
LLY Momentum
Is LLY Making Money?
Last year, LLY earnings were $5.24B. Over the past five year, LLY's earnings have grown by 13.14% per year. This was faster than the Drug Manufacturers - General industry average of 0.89%.
Last year, LLY revenue was $34.12B. During the past five year, LLY's revenue has gone up by 9.69% per year. This was faster than the Drug Manufacturers - General industry average of 7.1%.
Dig into LLY's earnings and revenue performance here.
Who is buying/selling LLY?
In the last 12 months, executives and large shareholders at LLY have sold more shares than they have bought.
Kimberly H. Johnson, Director of LLY, was the latest LLY insider to buy. They bought $9,760.01 worth of LLY stock on Apr 15, 2024.
Research more about who owns LLY stock here.
Can I rely on LLY as an income stream?
Eli Lilly & Co pays a dividend of 0.63%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.45%. If you owned $1,000 of LLY stock, you would have been paid $6.29 in the past 12 months.
Eli Lilly & Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more data about Eli Lilly & Co dividend yield and history here.
What others are saying about LLY
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Make your LLY buy order
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open Trade button and eToro will execute your order.
If you want additional help investing in stocks on eToro, watch the how to video below:
Step 6: Keep tabs on your LLY investment
Now that you own some LLY shares, you'll want to keep up with your company.
Create a watchlist to see the latest developments about your LLY stock.
LLY Feed
How to Buy Stock in Eli Lilly & Co
To reiterate, here are the 6 steps you need to take to buy Eli Lilly & Co stock right now:
- Figure out where to buy Eli Lilly & Co stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Evaluate Eli Lilly & Co stock
- Make your LLY buy order
- Keep tabs on your LLY investment
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Eli Lilly & Co, add LLY to your watchlist by clicking the button below.
Other Articles You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.